Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Cognitive Outcomes Among Patients with Hematological Cancer with Access to Computerized Cognitive Training: Results from a Feasibility Study

Samantha J Mayo, RN PhD, Eshetu G Atenafu, MSc, P.Stat, Sean B Rourke, PhD, John Kuruvilla, MD, Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3454.

https://doi.org/10.1182/blood.V130.Suppl_1.3454.3454

Published: 2017

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Donna Reece, BA, MD, John Mikhaeil, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Anca Prica, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 2010.

https://doi.org/10.1182/blood.V130.Suppl_1.2010.2010

Published: 2017

Journal Articles

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Amanda Li, MD BSc, Eshetu G Atenafu, M.Sc., P.Stat, Rosanne St. Bernard, MD MSc, Esther Masih-Khan, PhD, Donna Reece, MD FRCP(C), Norman Anthony Franke, MD, Rodger Tiedemann, MBChB, PhD, Anca Prica, MD FRCP(C), Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 4537.

https://doi.org/10.1182/blood.V130.Suppl_1.4537.4537

Published: 2017

Journal Articles

A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)

Cristina J. Gasparetto, MD, Suzanne Lentzsch, MD PhD, Gary J Schiller, MD, William Bensinger, MD, Nizar J. Bahlis, MD, Heather J. Sutherland, MD PhD FRCPC, Darrell J White, MD, Michael Sebag, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD, Richard LeBlanc, MDFRCPC, Christine I Chen, MD FRCP(C), Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Brea C. Lipe, MD

Blood (2017) 130 (Supplement 1): 3100.

https://doi.org/10.1182/blood.V130.Suppl_1.3100.3100

Published: 2017

Journal Articles

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Darrell J White, MD, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Gary J Schiller, MD, Cristina J. Gasparetto, MD, Heather J. Sutherland, MD PhD FRCPC, Michael Sebag, MD PhD, Suzanne Lentzsch, MD PhD, Rami Kotb, MD, William Bensinger, MD, Brea C. Lipe, MD, Christine I Chen, MD FRCP(C), Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Richard LeBlanc, MDFRCPC

Blood (2017) 130 (Supplement 1): 1861.

https://doi.org/10.1182/blood.V130.Suppl_1.1861.1861

Published: 2017

Journal Articles

Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2017) 130 (Supplement 1): 3057.

https://doi.org/10.1182/blood.V130.Suppl_1.3057.3057

Published: 2017

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Robert Frank Cornell, MD, Adriana C. Rossi, MDMSc, Rachid Baz, MD, Craig C Hofmeister, MDMPH, Chaim Shustik, MD, Joshua R Richter, MD, Christine I Chen, MD FRCP(C), Dan T. Vogl, MD, Erkan Baloglu, William Senapedis, PhD, Joel Ellis, PhD, Tony Williams, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2017) 130 (Supplement 1): 3134.

https://doi.org/10.1182/blood.V130.Suppl_1.3134.3134

Published: 2017

Journal Articles

Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)

Nizar J. Bahlis, MD, Heather Sutherland, MD, Darrell J White, MD, Michael Sebag, MD PhD, Suzanne Lentzsch, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD, Cristina J. Gasparetto, MD, Gary J Schiller, MD, Richard LeBlanc, MDFRCPC, William Bensinger, MD, Brea Lipe, MD, Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, BS, Jatin Shah, MD, Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3135.

https://doi.org/10.1182/blood.V130.Suppl_1.3135.3135

Published: 2017

Journal Articles

Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure

Christine I Chen, MD FRCP(C), Heather J. Sutherland, MD PhD FRCPC, Rami Kotb, MD, Michael Sebag, MD PhD, Darrell J White, MD, William Bensinger, MD, Cristina J. Gasparetto, MD, Richard LeBlanc, MDFRCPC, Christopher P. Venner, MD, Suzanne Lentzsch, MD PhD, Gary J. Schiller, Brea C. Lipe, MD, Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 3136.

https://doi.org/10.1182/blood.V130.Suppl_1.3136.3136

Published: 2017

NARROW

Cognitive Outcomes Among Patients with Hematological Cancer with Access to Computerized Cognitive Training: Results from a Feasibility Study

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)

Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only